I received a combined M.D. and PhD. Degree from the University at Buffalo. I then went on to UC San Diego in the physician-scientist training pathway for my residency and fellowship training where I also did a fellowship in Cancer Therapeutics Development, working in the lab of Tariq Rana on non-coding RNAs, RNA modifications, and large scale genomic screens using CRISPR-Cas9 in tumor xenografts. It is a privilege to return to Buffalo to serve patients and to join the research endeavor here at Roswell Park.
The lab is interested in early drug discovery using functional genomic screening. We have primarily been focusing on KRAS mutant solid tumors. Using a genome-wide CRISPR library, we have performed a large-scale screen directly in tumor xenografts harboring mutant KRAS and have identified a number of metabolic genes that are potential drug targets for KRAS mutant tumors. We have also identified a chromatin-remodeling complex subunit that may play a novel tumor suppressive role. We are interested in further drug discovery harnessing CRISPR screens. Other interests include biomarker assay development using CRISPR enzymes in ctDNA and elucidating epigenetic and epitranscriptomic contributions on cancer progression and resistance to therapy.
- Yau EH, Kummetha I, Lichinchi G, Tang R, Zhang Y, and Tariq TM. Genome-wide screen for essential cell growth mediators in mutant KRAS colorectal cancers. Cancer Res 2017 (accepted)
- Zhou Y, Dang J, Chang KY, Yau E, Aza-Blanc P, Moscat J, et al. miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3. Cancer Res 2016; 76(19):5777-87